Table 1.
Patients’ characteristics.
| Patients’ characteristics (n = 96) | |
|---|---|
| Female (%) | 37 (38) |
| Median (IQR) age (years) | 50.0 (39.0–58.5) |
| Median (IQR) disease duration (years) | 12.0 (6.5–19.5) |
| UC extensiona: E1/E2/E3 (%) | 14/45/36 (15/47/38) |
| Active smoking (%) | 9 (9) |
| Primary sclerosing cholangitis (%) | 8 (8) |
| Medication at moment of endoscopy (%) | |
| Mesalamine | 65 (67) |
| Steroids | 0 (0) |
| Immunosuppressantsb | 20 (21) |
| Anti-tumor necrosis factor4 | 32 (33) |
| Median (IQR) time in clinical remission since last relapse (months) | 27.0 (11.0–70.5) |
| Median (IQR) C-reactive protein (mg/l) | 1.2 (0.6–2.9) |
| Median (IQR) hemoglobin (g/dl) | 14.1 (12.9–15.3) |
| Median (IQR) WBC (109/l) (IQR) | 6.0 (5–7.9) |
| Median (IQR) platelets (109/l) | 251 (208–295) |
| Patients with Mayo endoscopic sub-score grade 0/1 (%) | 63/33 (66/34) |
| Patients with Geboes’ score ≥ 2B.1 (%) | 25 (26) |
| Patients with Geboes’ score ≥ 3.1 (%) | 22 (23) |
| Patients with diffuse/focal basal plasmacytosis (%) | 11 (12) |
a
UC extension according to Montréal classification (proctitis (E1), left-sided colitis (E2) extensive colitis (E3)). bImmunosuppressants, azathioprine, 6-mercaptopurine.
IRQ: interquartile range; UC: ulcerative colitis; WBC: white blood cells.